Phosphine

Phosphine

SCHEMBL9707943

COc1cc(CBr)cc(OC)c1OC.P

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 1/20 0.64
HTR2A P28223 1/20 0.57
HTR2C P28335 1/20 0.57
HTR2B P41595 1/20 0.57
ACHE P22303 1/20 0.52
TUBB4A P04350 3/20 0.52
TUBB P07437 3/20 0.52
TUBA3C P0DPH7 3/20 0.52
TUBA1B P68363 3/20 0.52
TUBA4A P68366 3/20 0.52
TUBB4B P68371 3/20 0.52
TUBB3 Q13509 3/20 0.52
TUBB2A Q13885 3/20 0.52
TUBB8 Q3ZCM7 3/20 0.52
TUBA3E Q6PEY2 3/20 0.52
TUBA1A Q71U36 3/20 0.52
TUBA1C Q9BQE3 3/20 0.52
TUBB6 Q9BUF5 3/20 0.52
TUBB2B Q9BVA1 3/20 0.52
TUBB1 Q9H4B7 3/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL722969 0.98 PTGS2 (0.67) PTGS2HTR2AHTR2CHTR2BACHE
SCHEMBL15271424 0.83 PTGS2 (0.50) PTGS2HTR2AHTR2CHTR2BACHE
SCHEMBL3127096 0.82 HTR2A (0.64) PTGS2HTR2AHTR2CHTR2BACHE
SCHEMBL4464142 0.80 HTR2A (0.75) PTGS2HTR2AHTR2CHTR2BACHE
SCHEMBL8910416 0.80 PTGS2 (0.70) PTGS2HTR2AHTR2CHTR2BACHE
SCHEMBL9085046 0.80 PTGS2 (0.47) PTGS2HTR2AHTR2CHTR2BACHE
SCHEMBL21980854 0.80 PTGS2 (0.47) PTGS2HTR2AHTR2CHTR2BTUBB4A
SCHEMBL6780613 0.79 HTR2A (0.60) PTGS2HTR2AHTR2CHTR2BACHE
SCHEMBL8067442 0.78 TUBB4A (0.54) PTGS2HTR2ATUBB4ATUBBTUBA3C
Bromide SCHEMBL28463593 0.78 PTGS2 (0.46) PTGS2HTR2AHTR2CHTR2BTUBB4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10952975-B2 Compositions and methods for treatment of cancer TERMAN DAVID S (US) 2021-03-23 US disclosed
US-20200297658-A1 Compositions and Methods for Treatment of Cancer TERMAN DAVID S (US) 2020-09-24 US disclosed
WO-1992016486-A1 SUBSTITUTED DIPHENYLETHYLENES AND ANALOGUES OR DERIVATIVES THEREOF ASTON MOLECULES LIMITED (GB) 1992-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200297658-A1 Compositions and Methods for Treatment of Cancer CD47, VEGFA, VHL PTGS2 819/4885HTR2A 3533/4885HTR2C 4304/4885
US-10952975-B2 Compositions and methods for treatment of cancer CD47, VEGFA, VHL PTGS2 819/4885HTR2A 3533/4885HTR2C 4304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.